Theravance Biopharma, Inc.

TBPH · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Assets
Cash & Equivalents$37,797$39,545$298,172$89,959
Short-Term Investments$50,553$62,881$29,312$83,506
Receivables$68,440$17,474$16,785$57,599
Inventory$0$0$0$0
Other Curr. Assets$4,277$13,641$9,195$18,806
Total Curr. Assets$161,067$133,541$353,464$249,870
Property Plant & Equip (Net)$35,772$45,355$52,001$53,347
Goodwill$0$0$0$0
Intangibles$0$0$0$0
Long-Term Investments$0$0$0$68,374
Tax Assets$0$0$0$0
Other NC Assets$157,322$203,103$201,935$3,228
Total NC Assets$193,094$248,458$253,936$124,949
Other Assets$0$0$0$0
Total Assets$354,161$381,999$607,400$374,819
Liabilities
Payables$2,242$1,524$1,554$3,098
Short-Term Debt$10,712$3,923$6,753$17,443
Tax Payable$5,853$0$0$0
Deferred Revenue$0$0$24$98
Other Curr. Liab.$13,278$19,320$20,384$37,948
Total Curr. Liab.$32,085$24,767$28,715$58,587
LT Debt$39,108$45,236$45,407$652,075
Deferred Rev, NC$0$0$192$310
Deferred Tax Liab, NC$0$0$0$240
Other NC Liab.$107,423$99,001$91,286$2,180
Total NC Liab.$146,531$144,237$136,885$654,805
Other Liabilities$0$0$0$0
Cap. Leases$49,820$49,159$52,160$52,681
Total Liabilities$178,616$169,004$165,600$713,392
Equity
Pref Stock$0$0$0$0
Common Stock$0$0$1$1
Retained Earnings-$965,522-$909,104-$853,911-$1,726,043
AOCI$7-$65-$15$0
Other Equity$1,141,060$1,122,164$1,295,725$1,387,469
Total Equity$175,545$212,995$441,800-$338,573
Supplemental Information
Minority Interest$0$0$0$0
Total Liab. & Tot. Equity$354,161$381,999$607,400$374,819
Net Debt$12,023$9,614-$246,012$579,559